Bairu Menghisteab 4

What Happened Bairu Menghisteab, a director of BrainStorm Cell Therapeutics, received an award of options to acquire 150,000 shares on February 26, 2026. The options have a reported acquisition price of $0.70 per share (150,000 × $0.70 = $105,000) and are reported as a derivative award (transaction code A).

Key Details

• Transaction date: 2026-02-26 (Form 4 filed 2026-05-20; filing was late)
• Award: Options for 150,000 shares at $0.70 per share (reported $105,000)
• Vesting: 50% vested on grant; remaining 50% vests six months after grant, contingent on continued service (see footnotes F1–F2)
• Plan: Granted under the Issuer's 2014 Stock Incentive Plan (footnote F1)
• Shares owned after transaction: Not specified in the filing
• Transaction type/code: Derivative grant / Code A (award/grant)

Context This was an option grant (an award), not a cash purchase or sale. Exercising the options in the future would require payment of the $0.70 exercise price per share and completion of the vesting conditions. The late filing delays public disclosure of the grant but does not, by itself, indicate the insider’s intent.